Novo Nordisk’s Oral Wegovy Wins Patient Preference as Long-Term Efficacy Data Strengthens Case
84% of patients prefer Novo Nordisk’s oral Wegovy over Lilly’s pill, with 14x lower dropout rate. Phase 3…
Solvay reports share buyback in the context of its long-term incentive plans
Press release Regulated information Brussels, May 11, 2026, 5:45pm CEST In accordance with article 8:4 of the Royal Decree…
New Research Bolsters Case for Long-Term Use of Novo Nordisk’s GLP-1 Drugs
New research shows discontinuing Wegovy/Ozempic leads to weight regain and a 22% higher heart attack/stroke risk, strengthening the…
Novo Nordisk Charts Long-Term Course with Major Irish Facility Investment
Novo Nordisk commits over €400M to expand Irish tablet plant for diabetes & obesity drugs, signaling long-term strategy…